deltatrials
Not Yet Recruiting NA INTERVENTIONAL 1-arm NCT04179045

A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

A Registry Trial of the Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART Ⅲ

Sponsor: CCRF Inc., Beijing, China

Conditions Coronary Artery Disease
Interventions The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
Updated 5 times since 2019 Last updated: Feb 23, 2021 Started: Mar 1, 2021 Primary completion: Jul 31, 2022 Completion: Jul 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Coronary Artery Disease and is currently actively recruiting participants. CCRF Inc., Beijing, China leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshotNot Yet Recruiting~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotNot Yet Recruiting~Mar 2021 – ~Jul 2024 · 40 months · monthly snapshotNot Yet Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotNot Yet Recruiting~Sep 2024 – present · 23 months · monthly snapshotNot Yet Recruiting

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Not Yet Recruiting NA

  2. Jul 2024 — Sep 2024 [monthly]

    Not Yet Recruiting NA

  3. Mar 2021 — Jul 2024 [monthly]

    Not Yet Recruiting NA

  4. Jan 2021 — Mar 2021 [monthly]

    Not Yet Recruiting NA

  5. Dec 2019 — Jan 2021 [monthly]

    Not Yet Recruiting NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • CCRF Inc., Beijing, China
  • Shanghai Bio-heart Biological Technology Co., Ltd.
Data source: Shanghai Bio-heart Biological Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations